Background: In cancer therapy, molecularly targeted agents have the potential to maximize antitumor efficacy while minimizing treatment-related toxicity. However, these agents may only be effective in specific tumor subtypes with defined genomic profiles. This emphasizes the importance of developing personalized cancer therapeutic strategies (i.e. through the use of companion diagnostic tests) to appropriately select and treat patients who are likely to benefit from specific targeted therapies, thus leading to improvements in clinical and safety outcomes. A potential biological target is the folate receptor (FR), which has been shown to be overexpressed on the surface of many cancers, including tumors of the lungs and ovaries.
introduction Molecular-targeted therapies have changed the prognosis of many tumor types; however, balancing the need to destroy cancerous cells with preserving healthy tissue and normal physiologic processes remains a challenge. Furthermore, inhibiting some cancer pathways through targeted therapies may adversely affect signaling pathways in normal cells, resulting in a spectrum of adverse events (AEs) often distinct from cytotoxic chemotherapy [1, 2] . As a paradigmatic example, although the effectiveness of bevacizumab has been seen in ovarian cancer [3] [4] [5] [6] [7] , predictive biomarkers are urgently needed for the careful selection of patients who are likely to respond to bevacizumab [8] and identification of patients who may be prone to serious toxicities, such as bowel perforation, fistula formation, thrombosis, renal dysfunction, and hypertension [7, 9] .
The search for good anticancer targets continues because of the heterogeneous and adaptive nature of many tumor types [1, 2, 10] . One potential target is the alpha isoform of the folate receptor (FR), which is selectively overexpressed in several tumor types, including ovarian cancer and nonsmall-cell lung cancer (NSCLC). In this review, we discuss the concept of personalized cancer therapy, the alpha isoform of the FR as a potential target for selected tumors, its role in both the diagnostic and therapeutic management of specific cancers, and how selectively targeting this receptor may be exploited in the context of personalized medicine.
personalized cancer therapy: the concept drives cancer growth. It is also affected by mechanisms the tumor uses to bypass the targeted pathway's oncogenic effects and how the patient processes the drug [10] .
Personalized medicine, also known as precision medicine [11] , is one of four pillars of systems medicine, which include predictive, preventive, and participatory medicine [12] . Personalized/ precision cancer therapy is based on the concept that patients can be selected for a specific targeted therapy based on molecular characterization of the tumor and its microenvironment, allowing administration of the right treatment to the right person at the right time [1, 13, 14] . Appropriate patient selection should translate into improved clinical outcomes, measured by response rate, survival, and safety [15] .
Biomarkers can be used to measure and evaluate disease prognosis objectively or as a predictor of response to a particular therapeutic intervention. Predictive biomarkers are particularly important in the context of targeted therapy, and a number of biomarker tests have been validated and approved by the US Food and Drug Administration [16] [17] [18] . As an example, we will use NSCLC. Patients with advanced NSCLC with specific EGFR mutations have a high likelihood of responding to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib [19, 20] . Similarly, crizotinib has been shown to be active in a small subgroup of patients with ALK rearrangements [21, 22] . For ovarian cancer, validated biomarkers are currently lacking, and research is ongoing to identify biomarkers for use in early detection, defining disease prognosis, predicting response to targeted therapies, and assisting in the planning of individualized treatment [23] .
Given that targeted agents often appear to give benefit only to a specific subtype of tumors with a defined genomic profile, it is essential that patients are appropriately selected for treatment. Thus, a need exists to develop and validate appropriate companion diagnostic tests of practical use in the clinical setting. Such tests must demonstrate a clear link between a particular molecular marker and a particular clinical outcome [14] .
role of the FR in cancer development, progression, and treatment
The folate cycle sustains key metabolic reactions and is essential for rapidly growing cells. Under physiologic conditions, exogenous reduced folates (water-soluble B vitamins) are predominantly transported into cells via the low-affinity, high-capacity, ubiquitously expressed reduced folate carrier (RFC; bidirectional anion-exchange mechanism) [24] [25] [26] . Once in the cell, folates play an essential role in the biosynthesis of purines and thymidine, which in turn are required for DNA synthesis, methylation, and repair [24, 25, 27] .
Folates are also transported by high-affinity FRs [25] . In humans, there are four isoforms of the FR (FRα, FRβ, FRγ, and FRδ) [28] [29] [30] . FRα, FRβ, and FRδ are attached to the cell surface by a glycosylphosphatidylinositol anchor, while FRγ is a secreted protein [27, 31] . A recent study demonstrated that the folate receptor 4 (FOLR4) gene encoded a protein unable to bind folic acid or reduced folate, which led investigators to rename the FRδ in Juno [31] . When folic acid or reduced folate binds to the FR, the cell-surface receptor-ligand complex is transported into the cell via receptor-mediated endocytosis for ligand release [28] . Table 1 shows the distribution of FR isoforms in normal and tumor tissue [27, [30] [31] [32] [33] [34] [35] . In the nonmalignant context, FRα tissue distribution is restricted to a limited number of polarized epithelia (uterus, placenta, choroid plexus, lung, and kidney), with expression localized at the apical/luminal surface of polarized cells, precluding contact with the circulation [27] [28] [29] . In contrast, FRα is overexpressed in the majority of tumors of the ovary, uterus, or ependymal brain and malignant pleural mesotheliomas, and is also overexpressed in a variable percentage of lung, kidney, breast, and colon carcinomas [27, 30, [32] [33] [34] . In the context of malignancy, it is noteworthy that FRα loses its polarized cellular location and instead, the entire cell surface is covered with FRα proteins. The role of FRα expression in tumors is unclear, but may involve modulation of folate uptake from serum [36] or activating signals associated with tumor growth [37] . In vitro and in vivo studies have demonstrated a correlation between human ovarian cancer growth and FR overexpression [38] . Inhibition of FRα expression in naturally expressing FRα-positive tumor cell lines also suppresses cell proliferation [39, 40] . In vivo studies in mouse tumor xenografts expressing human FRα have shown that anti-FRα mAbs suppress tumor growth [41] . Furthermore, FRα expression may also induce drug resistance by enhancing the antiapoptotic ability of tumor cells [42] . In addition, some evidence suggests that FRα overexpression is not altered after chemotherapy in ovarian and endometrial cancer [43, 44] and may represent a marker for resistance to conventional chemotherapy in ovarian cancer [42, 45] . The prognostic/predictive significance of FRα has been less intensively analyzed and, as a result, remains controversial. Furthermore, the differences in the survival associations of FRα expression that were observed in different histologic/gender subtypes suggest that there are differences in tumor biology [43] [44] [45] [46] [47] . Recently, an analysis of tissue microarray of ovarian cancer tumor samples found that FR expression in high-grade serous ovarian carcinoma was associated with increased overall survival (OS) in the first 2 years following diagnosis [48] . However, there is a decreased progression-free survival (PFS) interval associated with FR expression in clear-cell carcinoma [48] . As a result of these data, further analyses should be prospectively investigated in clinical trials.
Because FRα is expressed on the cell surface in a tumor-specific manner, it provides the potential to allow not only tumor localization, but also selected delivery of therapeutic agents to the malignant tissue, minimizing collateral toxic side-effects. There are a number of unique advantages to exploiting FR as a diagnostic and therapeutic target [30, 49] . First, FRα is located on the luminal surface of epithelial cells in most proliferating nontumor tissues and is inaccessible to circulation. In contrast, FRα is expressed all over the cell in malignant tissue and is accessible via circulation. Second, FR has the ability to bind to folic acid, a relatively innocuous, small molecule that can rapidly penetrate solid tumors and is amenable to chemical conjugation with other molecules. Once a folate conjugate is bound to FR, it is internalized into the cell and the FRα is rapidly recycled to the cell surface via the FR-mediated endocytic pathway, as depicted in Figure 1 [49, 50] . These factors all emphasize the potential role of FRα in the diagnosis and treatment of specific tumor types.
role of FR expression in personalized cancer therapy
Given that FR is expressed in only specific tumor subtypes, it may be a predictive biomarker for FR-directed therapy and useful as part of a personalized approach to treatment. Among the challenges of evaluating and validating cancer biomarkers is developing appropriate, robust, and practical measurement assays [51] . Various semiquantitative and quantitative methods have been used to assess FRα levels in tumor biopsy specimens or in the circulation; however, there are inherent challenges with many of these techniques, particularly in a clinical setting (Table 2) [42, 46, 47, [52] [53] [54] [55] [56] .
An attractive option is the in vivo use of a companion imaging agent that allows the whole-body, noninvasive, realtime assessment of FRα expression, facilitating the monitoring of FR status throughout the course of treatment without invasive tissue biopsies. Furthermore, FR expression on tumors can be heterogeneous and the molecular characteristics of tumors may change with time [57] [58] [59] , suggesting that reliance on historical balances to test for a target or mutation is unsatisfactory. The interaction between folic acid and FRα has been identified as a useful vehicle for allowing imaging probes to be localized on FR-expressing cells. The probe is conjugated to the folic acid molecule, binds with high affinity to the FR and emits an imaging signal. Current methods for detecting probe/folic acid conjugates include fluorescence imaging, magnetic resonance imaging, computed tomography, ultrasound imaging, singlephoton emission computed tomography (SPECT), and positron emission tomography. In the context of tumor imaging, a number of folate conjugates have been evaluated [60] [61] [62] [63] [64] [65] [66] [67] . One of particular interest is etarfolatide (EC20), an imaging agent composed of 99m technetium (Tc) complexed to a short folatelinked peptide (Figure 2A ) [68] . 99m Tc is a commonly used radiographic tracer that primarily decays by gamma emission and has a short half-life of around 6 h. When complexed to folic acid and injected into the circulation, it localizes to FR-expressing tissues and binds to the FR with high affinity. Uptake of 99m Tc-etarfolatide is high in FRα-positive tumors (∼17% injected dose/g tissue), with rapid accumulation in target tissue [60] . Expression of FR can then be visualized by SPECT (Figure 3 ) [69] . Importantly, excess probe conjugates are rapidly cleared from the blood via the kidneys, reducing nonspecific background and allowing images to be obtained quickly [60] .
In an initial exploratory study in 154 patients with solid tumors (mainly renal cell carcinomas), 99m Tc-etarfolatide was well tolerated with minimal toxicity [61] . In this study, patients received two i.v. injections: the first injection was 1 mg of folic acid (to reduce the uptake of 99m Tc-etarfolatide in normal tissues) and, 1-3 min later, 0.1 mg of 99m Tc-etarfolatide. Mean activity injected per kilogram of body weight was 10.73 MBq (range, 4.81-19.98 MBq/kg). Between 1 and 2 h after injection, anterior and posterior midthigh to head planar images were acquired with a dual-detector, large-field-of-view gammacamera equipped with low-energy, high-resolution, parallel-hole collimators. SPECT images of the region that was known to contain the target lesion(s) were obtained after planar imaging. One hundred five patients (68%) had at least one metastatic site that showed uptake of 99m Tc-etarfolatide (54% considered to have marked uptake and 46% had mild uptake). There were 17 AEs reported in 8% of patients receiving 99m Tc-etarfolatide, but only three events were considered to be 'possibly related' to study treatment. Tc-etarfolatide has also been used as the companion imaging agent in three phase II studies evaluating the FRtargeted drug conjugate vintafolide in patients with platinumrefractory epithelial ovarian, primary peritoneal, or endometrial cancer [69] ; progressive lung adenocarcinoma [70] ; and platinumresistant ovarian cancer [71] . The safety of 99m Tc-etarfolatide was The sensitivity is defined on the assay format in general; only in the case of radioligand binding assay is a specific reference for increase in sensitivity available. FR, folate receptor; IHC, immunohistochemistry; PCR, polymerase chain reaction. supported in each of these studies. A recent review commented on the use of 99m Tc-etarfolatide [72] as an FR-imaging agent to select for patients who are most likely to respond to FR-targeted therapy. However, these imaging results and their interpretation may be affected by a number of physiological and technical factors, including 99m Tc-etarfolatide uptake by several normal organs, possible false positivity in areas of infection or inflammation, and the use of separate SPECT and CT images [72] . In addition, a single-arm, open-label, exploratory study analyzing the correlation between FR expression by immunohistochemistry and 99m Tc-etarfolatide uptake reported an observed agreement between methods of 72% for positive results and 38% for negative results [61] .
FR-targeted therapeutics in personalized cancer therapy
The selective expression of the FR on cancerous tissues makes it attractive for targeted therapy. At present, two main strategies of FR-targeted therapy are in clinical development: folate conjugates and mAbs (Table 3 ) [73] [74] [75] [76] [77] . An alternative or even combinatorial strategy of FR-targeted therapy involves the development of antifolates that selectively target the FR [25] . One example is the novel FRα-targeted thymidylate synthase inhibitor, BGC 945 (ONX-0801), which is selectively transported into FRα-overexpressing tumors, potentially resulting in minimal toxicity to healthy tissue [78] . An ongoing phase I clinical trial is being conducted to assess the safety and pharmacokinetics of BGC 945 in patients with solid tumors (NCT02360345).
FR-targeted mAbs
Farletuzumab (MORab003) is a fully humanized FRα-binding mAb that does not prevent folate from binding to the FR nor does it block FR-mediated transport of folate into the cell [76, 77, 79] . Upon binding to FRα expressed on tumor cells, farletuzumab exerts its antitumor activity through different modes of action: (i) promotion of tumor cell lysis by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC); (ii) induction of sustained autophagy, resulting in a decrease in tumor cell proliferation; (iii) inhibition of the interaction between FRα and lyn kinase, thus reducing intracellular growth signaling. In a phase II study carried out in patients with platinum-sensitive recurrent ovarian cancer, farletuzumab in combination with carboplatin/taxane followed by singleagent farletuzumab maintenance demonstrated an improved overall response rate compared with historical controls [75] . Toxicity was generally favorable, with infrequent infusion reactions reported. Disappointingly, the efficacy data for farletuzumab in phase III clinical trials (NCT00849667 and NCT00738699) are conflicting. A large phase III study in patients with platinum-sensitive recurrent ovarian cancer evaluating farletuzumab in combination with carboplatin/taxane compared with carboplatin/taxane alone did not meet the primary end point of improving PFS [80] , although a recent post hoc exploratory analysis suggested an improved PFS in some patient subgroups [81, 82] . Farletuzumab was also investigated in a phase II placebocontrolled study in patients with metastatic adenocarcinoma of the lung with FRα-expressing tumors (NCT01218516); enrollment has been completed, but results were not available at the time of this review.
MOv18 immunoglobulin E (IgE) is a novel mouse/human chimeric IgE mAb engineered against FRα. MOv18 IgE was shown to be more efficacious than IgG1 in two ovarian tumor xenograft models [83, 84] . Furthermore, in vitro degranulation assays and the co-incubation of MOv18 IgE with serum samples from 21 patients with metastatic solid tumors suggested that MOv18 IgE may be an efficacious and safe candidate for clinical testing in FRα-positive tumors [85, 86] . As a result, a phase I, proof-of-concept study is planned (CRUKD/14/001).
folate cytotoxic drug conjugates
Covalent linkage of folate to a variety of molecules, including chemotherapy or imaging agents, allows targeted delivery to FRexpressing cells. For drug delivery, the folate-drug conjugate binds with high affinity and specificity to the FR and enters cells via endocytosis, often described as a 'molecular Trojan horse' [87] . According to recent unpublished experimental data (by the Matherly research group in collaboration with Endocyte), these conjugates do not appear to be substrates for the ubiquitously expressed RFC and may therefore selectively target tumor tissue (unpublished results). Furthermore, they do not interfere with the folate cycle or inhibit cellular uptake of antifolates such as methotrexate or pemetrexed.
Vintafolide is a water-soluble FR-targeting drug conjugate consisting of a folate moiety covalently linked via a peptide spacer and reducible disulfide linker to desacetylvinblastine monohydrazide (DAVLBH) ( Figure 2B ) [50, 68, 73, [88] [89] [90] . DAVLBH is a vinca alkaloid that prevents cell division through mitotic spindle inhibition, causing apoptosis of mitotically active cells [74] . Once vintafolide is endocytosed by the FRexpressing cell, the pH in the endosome decreases via proton pumps, the disulfide bond linking folate with DAVLBH is cleaved through a reductive process, and the drug is released (Figure 1) [50, 68, 73] . Because vintafolide directly targets FRexpressing cells, non-FR-expressing cells have limited exposure to DAVLBH [88] .
vintafolide clinical trials
After antitumor activity was reported in a phase I dose-escalation study of vintafolide in patients with refractory or metastatic cancer [91] , a phase II clinical program was initiated evaluating vintafolide in patients with platinum-refractory epithelial ovarian, primary peritoneal, or endometrial cancer [69] ; progressive lung adenocarcinoma [70] ; and platinum-resistant ovarian cancer (PRECEDENT) [71] . Before treatment, expression of functionally active FR was evaluated by SPECT with 99m Tc-etarfolatide. Patients were categorized according to the presence of functionally active FR expression on lesions selected according to Response Evaluation Criteria in Solid Tumors (RECIST): patients with 100% of selected lesions that were FR positive were categorized as FR++, patients with at least one selected lesion that was FR positive (10%-90%) were classified as FR+, and those with no FRpositive lesions (0%) were classified as FR−.
lung cancer
Clinical benefit of vintafolide in patients with recurrent or refractory adenocarcinoma of the lung was evaluated in an openlabel study [70] . Patients who had received at least two prior chemotherapy regimens (n = 43) and had at least one lesion with FR expression were treated with induction vintafolide (1.0-mg/ day i.v. bolus on days 1-5, 8-12, and 15-19, every 4 weeks for two cycles), then maintenance vintafolide (2.5 mg i.v. three times weekly on weeks 1 and 3 of a 4-week cycle). In the overall study population, the primary objective of clinical benefit (defined as an ability to receive at least four cycles of therapy) was not met (26% Tc-etarfolatide during the study-screening period), compared the addition of vintafolide to docetaxel with docetaxel alone in patients with advanced NSCLC in whom one prior chemotherapy regimen had failed. The primary end point of the study was PFS [92] . Vintafolide in combination with docetaxel showed clinically meaningful improvement across all efficacy end points over single-agent docetaxel, and the best improvement was seen in the predefined adenocarcinoma patient subgroup: PFS HR of 0.68 [95% confidence interval (CI) 0.41-1.14], OS HR of 0.51 (0.28-0.94). The safety profile was manageable.
ovarian cancer
In the first of the phase II studies, vintafolide was evaluated in 43 women with recurrent or persistent platinum-resistant epithelial ovarian, primary peritoneal, or peritoneal carcinoma [69] . Patients were treated with induction vintafolide (as in lung cancer), then patients without disease progression received maintenance vintafolide (as in lung cancer). FR status appeared to have an impact on outcome: median OS was 14.6 months in patients with FR++ tumors, 9.6 months in patients with FR+ tumors, and 3.0 months in patients with FR− tumors. Furthermore, patients with FR++ tumors had a disease control rate of 57% versus 36% in FR+ patients and 33% in FR− patients. Common drugrelated AEs (all grades) were constipation (45%), fatigue (37%), nausea (29%), anorexia (22%), and neuropathy (20%). There were no grade 4 drug-related toxicities.
Addition of vintafolide to pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer was investigated in the open-label, phase II PRECEDENT study [71] . Patients were randomly assigned to vintafolide (2.5 mg i.v. three times weekly on weeks 1 and 3) in combination with PLD 50 mg/m 2 i.v. every 28 days (n = 100) or PLD alone (same dose and schedule; n = 49). In the overall intent-to-treat population, median PFS was 5.0 months in the vintafolide-plus-PLD arm versus 2.7 months for PLD alone (HR 0.626; 95% CI 0.409-0.959; P = 0.031). In addition, patients with FR+ lesions had notable relative PFS gains with vintafolide plus PLD (median 5.7 months) compared with PLD alone (median 1.7 months; HR 0.547; 95% CI 0.304-0.983; P = 0.041) and FR++ patients had a significant improvement in median PFS with vintafolide plus PLD (5.5 months) compared with PLD alone (1.5 months; HR 0.381; 95% CI 0.172-0.845; P = 0.013). In the overall study population, the drug combination was well tolerated. Most treatment-emergent AEs were grade 1 or 2 in severity, with the incidence of all-grade leukopenia, abdominal pain, peripheral sensory neuropathy, and neutropenia significantly higher in the vintafolide-plus-PLD arm than in the PLD-alone arm. Febrile neutropenia and infections were rare in either treatment arm.
A phase III, randomized, double-blind study (PROCEED, NCT01170650) in FR-positive patients (as determined by 99m Tc-etarfolatide imaging during study-screening period) is comparing vintafolide in combination with PLD with PLD alone in women with platinum-resistant ovarian cancer. The primary end point is PFS, measured per RECIST 1.1. At a prespecified interim futility analysis, the Data Safety Monitoring Board (DSMB) recommended that the PROCEED trial be prematurely stopped because the comparison did not meet the prespecified criteria for PFS to allow study continuation [93] , and steps were subsequently taken to terminate the trial [94] . The DSMB did not identify any safety concerns for the patients enrolled in the study.
The published clinical data indicate that treatment with vintafolide is associated with improved clinical outcomes in patients with tumors that have a high 99m Tc-etarfolatide uptake (FR++ lesions). This suggests that tumor FR expression may be an important and useful predictive biomarker for selection of patients who will benefit from vintafolide. As a result, studies that specifically enrich patients with FR-positive tumors should provide further insight into the utility of FR-targeted agents.
conclusions
The FR plays an important role in cancer development and progression, and FR-targeted therapies have led to a need for reliable methods for detecting FR-positive tumors to help select patients who may benefit from treatment.
Results from phase II clinical studies in ovarian and lung cancer demonstrated that both mAb-based and folate-conjugate therapeutic modalities improved outcomes in patients with FRpositive tumor. However, when evaluated in advanced-stage platinum-resistant ovarian cancer in phase III trials, the two modalities failed to reach their primary end point or did not meet the prespecified criteria for PFS, respectively. In particular, the analysis of two phase II studies emphasized the poor prognosis of patients with platinum-resistant recurrent ovarian cancer with FR-expressing tumors compared with those without FR expression when treated with standard chemotherapy. Therefore, the disappointing results seen in phase III studies may be partially attributed to the selection of patients with aggressive disease and a poor prognosis who were unable to respond sufficiently to these therapeutic agents. The disappointing results seen in phase III farletuzumab clinical trials may also be explained by the lack of a priori patient selection for FR expression and farletuzumab's described mechanisms of action, which require a preserved immune system. On the other hand, the effectiveness of vintafolide may be limited by its ability to recognize both the α and β isoforms of FR (similar to 99m Tcetarfolatide) and present a certain degree of toxicity.
In any case, the results of phase II clinical trials indicate that 99m
Tc-etarfolatide is a promising biomarker of response to vintafolide and other FR-targeted therapies, which is a much-needed personalized approach to therapy. The agreement between 99m Tc-etarfolatide imaging results and immunohistochemistry was limited for negative cases, and this relatively low specificity of the in vivo methods could be attributed to 99m Tc-etarfolatide binding to both the α and β isoforms of FR. In contrast, only the α isoform of FR is detected with immunohistochemistry. Furthermore, the time of tissue sampling and the time of 99m Tcetarfolatide imaging were different. Overall, these data suggest that even if the use of 99m Tc-etarfolatide as an imaging agent is likely to provide an accurate assessment of predicted response to folate-conjugate therapy, further immunohistochemical evaluation of tumors that have been infiltrated by activated macrophages expressing FRβ may be required, and other companion diagnostics suitable for either of the two therapeutic approaches (folate conjugates and mAb-based therapy) should be developed. Additional ongoing studies of vintafolide in FR-positive patients selected with 99m Tc-etarfolatide and future welldesigned studies would help to further define which patients will receive the most benefit from treatment and to confirm the correlation between companion diagnostic results and response to FR-targeted therapy.
Finally, many challenges remain with these agents, which can potentially limit their therapeutic activities (i.e. toxicity and drug resistance) or their predictive value as appropriate, robust, and practical companion diagnostic assays. Future predictive biomarker studies and clinical trials must account for many factors, including study design (i.e. sample size and selection of eligible patients), interpretation of results (i.e. qualitative versus quantitative predictive effects), and factors surrounding the clinical utility of biomarkerbased tests and new therapeutic approaches (i.e. toxicity and cost). TT has been an advisory board member for Endocyte, Inc. All remaining authors have declared no conflicts of interest.
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